Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a perceived rise in political risk.

| More on:
Frustrated young white male looking disconsolate while sat on his sofa holding a beer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s a FTSE stock in my portfolio that looks like it’s just done a couple of rounds with Mike Tyson (the young version). It’s down 26% in just 10 days and now trades for 22p.

The stock is hVIVO (LSE: HVO), a small-cap from the FTSE AIM 100 index. There’s been no significant news published during this time, other than Octopus Investments (the firm’s largest shareholder) increasing its stake from 12.32% to 13.32%. That’s a positive sign.

So what’s going on here? And is this a chance for me to buy more shares? Let’s dig in.

Ask questions later

hVIVO conducts human challenge trials for biopharma companies, which involves exposing healthy volunteers to pathogens under controlled conditions. These provide quicker data, cut costs, and can speed up the clinical trial process.

Now, exact figures aren’t publicly disclosed, but it’s safe to assume that a substantial portion of hVIVO’s business is involved in testing vaccine candidates. And here’s the issue with the share price.

Donald Trump has nominated vaccine sceptic Robert F Kennedy Jr to be the next US health secretary. He’s promised to let Kennedy “go wild on health”.

If he gets this position (which looks likely but isn’t certain), his potential influence over vaccine policies might have significant implications for hVIVO.

For example, he could use his public position to cast doubt on the efficacy of vaccines, potentially leading many American families to skip them. This might force pharmaceutical companies to deprioritise vaccine research and development (R&D).

Pharma firms frequently receive research grants from federal bodies for vaccine R&D. This funding could be cut, resulting in less trials taking place.

These risks appear to have caused investors to sell the stock now and ask questions later.

H1 results

In H1, hVIVO reported record revenue of £35.6m, which was 30.6% higher than the year before. The EBITDA margin was around 24%, up from 19% in H1 2023.

Looking ahead, the company has set a medium-term revenue target of £100m by 2028. That would be solid growth from last year’s £56m.

In the H1 report, CEO Yamin Khan said: “We have full visibility over our expected 2024 revenues…I believe we have laid the foundations for strong performance in the months and years ahead.”

After this sell-off, the stock trades on a forward price-to-earnings (P/E) ratio of 13. That looks dirt cheap and I reckon it will claw back some losses if management offers a reassuring trading update.

Of course, if the opposite happens, the stock could fall further.

What to do?

I won’t get into the weeds on vaccines here. But it’s no coincidence that the deadly smallpox virus was eradicated in 1980 after a global vaccination campaign. Outbreaks of Covid, measles, mumps, polio, and much more, are also down significantly.

Longer term, I have confidence in the fields of vaccine R&D, human challenge trials, and the progress of medical science.

However, facts and investor sentiment are two separate things entirely. And the medium-term future is cloudier for hVIVO’s orderbook growth than it was just a few weeks ago.

I recently took the opportunity to buy a few more shares at 21p. So I clearly don’t think it was madness for me to invest after the 26% drop. But I won’t be chasing the stock any lower.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Best British value stocks to consider buying in December

We asked our freelance writers to reveal their top value shares, including one 'Fire' and one 'Ice' recommendation...

Read more »

Dividend Shares

£3k in savings? Investors could consider putting it here for juicy second income

Jon Smith talks through how investors could buy dividend stocks with yield potential in excess of 6.5% for second income

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

Why the boohoo share price soared by almost 14% in November

Is troubled online fashion retailer boohoo beginning a turnaround that may cause the share price to rocket through 2025 and…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

Here’s how saving £5.40 a day could net me £1,971 yearly passive income for life

The price of a cup of coffee seems to have broken the £5 mark. Is it time to put that…

Read more »

Investing Articles

2 top FTSE 100 stocks surging to record highs (hint — not Rolls-Royce)!

Ben McPoland takes a closer look at a pair of high-performing FTSE 100 stocks that continue to enrich long-term shareholders.

Read more »

Investing Articles

A cheap FTSE 100 share to consider buying for the next 10 years!

This FTSE 100 share has pride of place in my portfolio. Here's why I think it could be a top…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 44% in 2 months! Is this FTSE 250 green energy pioneer priced too cheaply?

After a sharp tumble in recent months, this FTSE 250 company with a growing order book is almost 90% below…

Read more »

Investing Articles

Investing a £20k Stocks and Shares ISA in this high-yielder might give me a £2,000 annual income

Harvey Jones is now wondering whether to pour his entire Stocks and Shares ISA allowance into a single FTSE 100…

Read more »